199 related articles for article (PubMed ID: 12520634)
1. Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
Kerr D
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):12-5. PubMed ID: 12520634
[TBL] [Abstract][Full Text] [Related]
2. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine/irinotecan combination regimens in colorectal cancer.
Kerr DJ
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):27-9. PubMed ID: 12014865
[TBL] [Abstract][Full Text] [Related]
4. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Cartwright T; McCollum D; Boehm KA
Am J Clin Oncol; 2010 Jun; 33(3):307-13. PubMed ID: 20375835
[TBL] [Abstract][Full Text] [Related]
5. Current status of adjuvant therapy for colorectal cancer.
O'Connell MJ
Oncology (Williston Park); 2004 May; 18(6):751-5; discussion 755-8. PubMed ID: 15214594
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer: chemotherapy treatment overview.
Royce ME; Medgyesy D; Zukowski TH; Dwivedy S; Hoff PM; Pazdur R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):40-6. PubMed ID: 11200148
[TBL] [Abstract][Full Text] [Related]
7. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
[TBL] [Abstract][Full Text] [Related]
8. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Van Cutsem E; Verslype C; Tejpar S
Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
[TBL] [Abstract][Full Text] [Related]
9. [Capecitabine and irinotecan].
Gasperoni S
Suppl Tumori; 2004; 3(4):S107-8. PubMed ID: 15206231
[No Abstract] [Full Text] [Related]
10. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Hofheinz RD; Gnad-Vogt U; Wein A; Saussele S; Kreil S; Pilz L; Hehlmann R; Hochhaus A
Anticancer Drugs; 2005 Jan; 16(1):39-45. PubMed ID: 15613902
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Moosmann N; Heinemann V
Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
Choi CK; Chan RT; Tung SY; Lui L; Siu S; Au GK; Ho JW; Law WL
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):168-75. PubMed ID: 18155454
[TBL] [Abstract][Full Text] [Related]
13. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Montagnani F; Chiriatti A; Licitra S; Aliberti C; Fiorentini G
Clin Colorectal Cancer; 2010 Oct; 9(4):243-7. PubMed ID: 20920997
[TBL] [Abstract][Full Text] [Related]
14. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Twelves C
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):23-6. PubMed ID: 12520636
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Jordan K; Kellner O; Kegel T; Schmoll HJ; Grothey A
Clin Colorectal Cancer; 2004 May; 4(1):46-50. PubMed ID: 15207020
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
Assy N; Basher W; Chetver L; Shnaider J; Zidan J
J Clin Gastroenterol; 2012 Apr; 46(4):e27-30. PubMed ID: 22392022
[TBL] [Abstract][Full Text] [Related]
18. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the use of irinotecan in colorectal cancer.
Cunningham D; Maroun J; Vanhoefer U; Van Cutsem E
Oncologist; 2001; 6 Suppl 4():17-23. PubMed ID: 11585970
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]